OREANDA-NEWS. The EIB will provide financing of EUR 25 million to the Austrian biotech company Apeiron Biologics AG (Apeiron). The financing will support the development of new pharmaceutical products to treat cancer, particularly a rare type affecting children. The transaction with Apeiron was made possible by the support of the «European Fund for Strategic Investments» (EFSI). EFSI is the central pillar of the «Investment Plan for Europe», with which the EIB Group and the European Commission as strategic partners aim to boost the competitiveness of the European economy.